Core Insights - Xtant Medical reported modest revenue growth in Q4 2025, with revenue reaching $32.4 million, a 3% increase from $31.5 million in the prior year [2][6]. - The company achieved a full-year revenue of $133.9 million for 2025, reflecting a 14% increase from $117.3 million in 2024, and marked a return to profitability with a net income of $5.0 million [6][11][8]. - The divestiture of non-core assets to Companion Spine for approximately $21.4 million has reshaped the company's focus towards its core biologics business [12][5]. Financial Performance - Operating expenses for Q4 2025 were $18.7 million, up from $17.9 million in the comparable 2024 period, with general and administrative expenses increasing to $7.3 million [1][10]. - Gross margin improved to 54.9% in Q4 2025 from 50.8% a year earlier, attributed to a favorable sales mix and greater scale [2][9]. - Full-year gross margin increased to 62.9% from 58.2% in 2024, with about 530 basis points of improvement from sales mix and scale [9]. Strategic Focus - The company plans to guide 2026 revenue between $95 million and $99 million, anticipating sequential growth driven by an expanded salesforce and new product launches [4][18]. - Xtant has doubled its regional sales representatives and plans to enhance its national accounts team to drive institutional adoption [14]. - New product launches, including nanOss Strata and CollagenX, are expected to accelerate growth in the biologics segment [15][16]. Cash and Capital Management - Year-end cash totaled $17.3 million, significantly up from $6.2 million a year earlier, bolstered by proceeds from the divestiture [12]. - The company does not anticipate the need for additional outside capital in the foreseeable future [12][21]. Market Outlook - The company expects sequential quarter-over-quarter growth through 2026, despite anticipated declines in certain product lines due to the divestiture and expiration of license revenue [19][20]. - Gross margin for 2026 is expected to remain in the low 60% range, supported by higher-margin biologics launches [21].

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][13] - For the full year 2025, total revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [7][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full-year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, compared to a net loss of $3.2 million in Q4 2024, and for the full year, net income was $5 million, compared to a net loss of $16.5 million in 2024 [16][19] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, but it is expected to grow due to increased investments in the sales force and new product launches [7][12] - The gross margin for Q4 2025 was 54.9%, up from 50.8% in Q4 2024, driven by a favorable sales mix and greater scale [14] - For the full year 2025, gross margin improved to 62.9% from 58.2% in 2024, with 530 basis points of the increase attributed to sales mix and scale [17] Market Data and Key Metrics Changes - The company anticipates organic growth in its core biologics business to accelerate in 2026, despite headwinds from the divestiture of the Companion Spine business and the expiration of certain license revenues [12][25] - The hardware business is expected to decline at a steady rate, approaching high teens percentage in 2026 [31][46] Company Strategy and Development Direction - The company has sharpened its focus on its core high-margin biologics business, which is seen as a key area for growth [6][8] - The strategic initiatives include in-house manufacturing to improve quality and control costs, and a disciplined approach to operating expenses [8][12] - The company plans to double the number of regional sales representatives and add resources to the national accounts team to drive institutional adoption [9][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining positive cash flow and does not anticipate the need for additional outside capital [5][12] - The company expects to see a ramp-up in its advanced wound care business as it transitions to selling under its own brand [27][28] - Management highlighted the importance of innovation and new product launches, including nanOss Strata and CollagenX, which are expected to enhance growth prospects [10][11] Other Important Information - The company completed the sale of non-core assets for approximately $21.4 million, which has strengthened its cash position [5][6] - As of December 31, 2025, the company had $17.3 million in cash equivalents, significantly up from $6.2 million a year prior [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics - Management expects sequential quarter-over-quarter growth in 2026, driven by new product offerings and an expanded commercial organization, but notes seasonality will affect growth rates [25] Question: Headwinds from loss of license revenue related to Q-Codes - Management acknowledged the loss of Q-Code revenue but anticipates a ramp-up in sales under the Xtant brand as the year progresses [27][28] Question: Decline in hardware business throughout 2026 - Management expects a slow decline in the hardware business throughout the year, with a steady rate approaching high teens percentage [31] Question: Growth drivers in biologics and distribution channels - Key growth drivers include advanced biologics products and a focus on Xtant branded products through independent agent networks, with a significant portion of growth expected from these channels [36][40]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][14] - Full year 2025 revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [7][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, or $0.00 per share, compared to a net loss of $3.2 million, or $0.02 per share in Q4 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, with a focus on high-margin products expected to drive future growth [7][8] - Sales and marketing expenses for Q4 2025 were $10.9 million, down from $11.7 million in Q4 2024, primarily due to reduced commission expenses [15] - Research and development expenses decreased to $459,000 in Q4 2025 from $522,000 in Q4 2024 [15] Market Data and Key Metrics Changes - The company anticipates continued organic growth in its core biologics business, with expectations for revenue in 2026 to be between $95 million and $99 million [12] - The loss of license revenue from Q-Code and amniotic membrane agreements is expected to impact 2026 revenue, but the company is optimistic about ramping up its advanced wound care products [28][29] Company Strategy and Development Direction - The company has sharpened its focus on its core high-margin biologics business following the sale of non-core assets, which is seen as a transformational move [5][6] - Plans to double the number of regional sales representatives and expand the national accounts team are in place to drive institutional adoption and revenue growth [9][12] - The company is committed to maintaining positive free cash flow and does not anticipate the need for additional outside capital [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational discipline and the successful execution of strategic initiatives aimed at self-sustainability and cash flow generation [8][12] - The outlook for 2026 includes expectations for sequential quarter-over-quarter growth, driven by new product offerings and an expanded commercial organization [26] Other Important Information - The gross margin for Q4 2025 was 54.9%, an increase from 50.8% in Q4 2024, attributed to a favorable sales mix [14] - The company had $17.3 million in cash equivalents and restricted cash as of December 31, 2025, compared to $6.2 million a year earlier [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics business - Management expects sequential quarter-over-quarter growth in 2026, with biologics in Q1 anticipated to be down low double digits compared to Q1 2025 due to headwinds from lost amnio product [26][27] Question: Impact of loss of license revenue from Q-Codes - The Q-Code revenue will completely go away, but management anticipates ramping up sales of their own branded products in advanced wound care as the year progresses [28][29] Question: Decline in hardware business throughout 2026 - A slow decline in the hardware business is expected throughout the year, with a projected decline approaching high teens percentage [31] Question: Growth drivers in biologics and distribution channels - Key growth drivers include advanced biologics products like OsteoVive Plus and CollagenX, with approximately 20-22% of growth expected from OEM channels [36][40] Question: Strategic thoughts on hardware business and gross margin in 2026 - Management is evaluating the hardware business as a potential strategic distraction but sees current offerings as strong. Gross margin for 2026 is expected to be in the low 60s percentage [46][48]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][12] - Full year 2025 revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [6][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, compared to a net loss of $3.2 million in Q4 2024, and full year net income was $5 million, compared to a net loss of $16.5 million in 2024 [16][19] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, but is expected to grow due to new product launches and increased sales force [6][8] - The sale of non-core assets to Companion Spine was transformational, allowing the company to focus on high-margin biologics [5][11] - Gross margin for Q4 2025 was 54.9%, up from 50.8% in Q4 2024, driven by a favorable sales mix [14] Market Data and Key Metrics Changes - The company anticipates organic growth in its core biologics business, despite headwinds from the divestiture and loss of license revenue [11][12] - The hardware business is expected to decline at a steady rate, approaching high teens percentage in 2026 [30] Company Strategy and Development Direction - The company is focused on self-sustainability, positive cash flows, and tighter operating discipline, with a strategic emphasis on in-house manufacturing [7][11] - Plans to double the number of regional sales representatives and expand the national accounts team to drive institutional adoption [8][11] - Continued investment in R&D and new product introductions is central to the company's growth strategy [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and foundation for growth, with a revenue outlook for 2026 projected between $95 million and $99 million [11][12] - The company expects to maintain positive free cash flow and does not anticipate the need for additional outside capital [5][11] Other Important Information - The company completed the sale of its Coflex assets for approximately $21.4 million, which has strengthened its cash position [5][6] - Cash equivalents and restricted cash as of December 31, 2025, were $17.3 million, up from $6.2 million in 2024 [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics business - Management expects sequential quarter-over-quarter growth in 2026, driven by new product offerings and an expanded commercial organization [24] Question: Headwinds from loss of license revenue related to Q-Codes - The Q-Code revenue will cease, but management anticipates ramping up sales under the Xtant brand as distributors shift to using their contracts [26] Question: Decline in hardware business throughout 2026 - A slow decline in the hardware business is expected, with a steady rate approaching high teens percentage [30] Question: Specific products expected to support biologics growth - Key products include OsteoVive Plus, OsteoFactor Pro, and CollagenX, with significant growth opportunities identified [34] Question: Growth channels for biologics business - The majority of growth is expected to come from Xtant branded products through independent agent networks, with OEM channels contributing around 20% [38][42] Question: Strategic thoughts on the hardware business - The hardware business is still beneficial for the biologics segment, but management is evaluating its long-term strategic value [45]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $33.3 million, a 19% increase from $27.9 million in Q3 2024, primarily driven by $5.5 million in licensing revenue [13][14] - Gross margin improved to 66.1% in Q3 2025 from 58.4% in Q3 2024, attributed to a favorable sales mix and greater scale [14] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5 million in the same period last year [16] Business Line Data and Key Metrics Changes - The biologics product family, the core business, grew 4% year-over-year, which was below long-term growth expectations [8][9] - Hardware product revenue declined by 6% or $736,000 year-over-year [13] Market Data and Key Metrics Changes - The company anticipates closing the sale of non-core assets for $19.2 million, which will enhance focus on core biologics and strengthen financial position [5][6] - The sale is expected to be neutral to slightly positive for margins and bottom line metrics in 2026 and beyond [7] Company Strategy and Development Direction - The company is focusing on self-sustainability and positive cash flows, with strategic initiatives aimed at higher margin biologics and in-house manufacturing [9] - Investments are being made in the commercial team to maximize the reach of the orthobiologics portfolio [9][10] - New product launches include CollagenX, which is designed for surgical wound closure and complements the existing product line [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving low double-digit growth in the orthobiologics business for 2026, despite not providing full guidance yet [23][24] - The company is optimistic about the impact of new products and the potential for growth in the surgical repair and wound care markets [11][40] Other Important Information - The company has $10.6 million in cash and equivalents, with $25.6 million in net accounts receivable and $40.7 million in inventory as of September 30, 2025 [17] - The anticipated proceeds from the sale of assets will not require additional external capital for operations [5][6] Q&A Session Summary Question: Plans for investment in the commercial organization - Management indicated plans to increase the number of sales representatives from four to eight by the end of the year, with further additions expected in 2026 [22] Question: Growth expectations for the orthobiologics business - Management expects low double-digit growth in orthobiologics for 2026, with ongoing efforts to optimize the product portfolio [23][24] Question: Insights on new product launches at NAS - Management highlighted three key products: a new growth factor product, an advanced DBM called Trivium, and the recently launched CollagenX [24][25] Question: Year-over-year growth in orthobiologics - The 4% growth was supported by the stem cell and amnio product lines, while older demineralized bone products faced declines [30][31] Question: Impact of amnio product pricing changes - The company is well-positioned to benefit from the new pricing structure in the amnio market due to its low production costs [36][38] Question: Plans for distributing CollagenX - Management sees significant potential for CollagenX in various surgical procedures and is excited about its market opportunities [40]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $33.3 million, a 19% increase from $27.9 million in Q3 2024, primarily driven by $5.5 million in licensing revenue [13][14] - Gross margin improved to 66.1% in Q3 2025 from 58.4% in Q3 2024, attributed to a favorable sales mix and greater scale [14] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5 million in the same period last year [16] Business Line Data and Key Metrics Changes - The biologics product family, the core business, grew 4% year-over-year, which was below long-term growth expectations [8][9] - Hardware product revenue declined by 6% or $736,000 year-over-year [13] Market Data and Key Metrics Changes - The company anticipates closing the sale of non-core assets for $19.2 million, which will enhance focus on core biologics and strengthen financial position [5][6] - The anticipated revenue from the sold business was approximately $23.5 million, which was modestly unprofitable on a standalone basis [7] Company Strategy and Development Direction - The company is focusing on self-sustainability and positive cash flows, with strategic initiatives aimed at higher margin biologics and in-house manufacturing [9] - Investments are being made in the commercial team to maximize the reach of the orthobiologics portfolio [9][10] - New product launches include CollagenX, which is expected to complement existing offerings and address diverse surgical needs [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving low double-digit growth in the orthobiologics business for 2026, despite not providing specific guidance yet [23][24] - The company is optimistic about the impact of new products and the potential for growth in the surgical repair and wound care markets [11][40] Other Important Information - The company has reiterated its 2025 revenue guidance of $131 million to $135 million, reflecting an 11%-15% growth over 2024 [12] - Cash balance as of September 30, 2025, was $10.6 million, with net accounts receivable at $25.6 million and inventory at $40.7 million [17] Q&A Session Summary Question: Plans for commercial organization investments - Management indicated plans to increase the number of sales representatives from four to eight by the end of the year, with further additions expected in 2026 [22] Question: Growth expectations for orthobiologics business - Management expects low double-digit growth in orthobiologics for 2026, with ongoing efforts to optimize the product portfolio [23][24] Question: Highlights for upcoming NAS event - Management highlighted new products such as a growth factor product, advanced DBM called Trivium, and CollagenX as key offerings to showcase [25] Question: Year-over-year growth in orthobiologics - Management noted a 4% growth in orthobiologics, driven by stem cell and amnio product lines, while older demineralized bone products faced challenges [30][31] Question: Impact of amnio product pricing changes - Management expressed confidence in leveraging robust hospital contracts to capitalize on new pricing structures in the amnio market [36][38] Question: Plans for CollagenX distribution - Management sees significant potential for CollagenX in various markets, leveraging existing platforms and FDA work for future growth [40]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $33.3 million, a 19% increase from $27.9 million in Q3 2024, primarily driven by $5.5 million in licensing revenue and $576,000 in additional biologics revenue, despite a 6% decline in hardware product revenue [13][8][4] - Gross margin improved to 66.1% in Q3 2025 from 58.4% in Q3 2024, attributed to a favorable sales mix and greater scale [13] - Net income for Q3 2025 was $1.3 million, compared to a net loss of $5 million in the same period last year [16] - Adjusted EBITDA for Q3 2025 was $4.5 million, a significant improvement from an adjusted EBITDA loss of approximately $1 million in Q3 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family, the core business, grew by 4% year-over-year, which was below long-term growth expectations [8] - The company is focusing on higher-margin biologics and in-house manufacturing to improve quality and control costs, with plans to drive top-line growth in the orthobiologics business [9] Market Data and Key Metrics Changes - The company anticipates closing the sale of non-core assets for $19.2 million, which will enhance focus on the core biologics business and strengthen financial position [5][6] - The anticipated revenue from the sold business was approximately $23.5 million, which was modestly unprofitable on a standalone basis [6] Company Strategy and Development Direction - The company is shifting focus back to driving top-line growth in orthobiologics after achieving self-sustainability and positive cash flows [9] - New product launches include CollagenX, which is designed for surgical wound closure and complements the existing orthobiologics product line [10] - The company is well-positioned to grow in the surgical repair and wound care markets, supported by positive feedback from surgeons on recent innovations [11] Management's Comments on Operating Environment and Future Outlook - Management reiterated 2025 revenue guidance of $131 million to $135 million, reflecting an 11%-15% growth over 2024 revenue [11][12] - The company expects to provide initial 2026 revenue guidance with Q4 results in March of next year [12] Other Important Information - The company has $10.6 million in cash and cash equivalents, with net accounts receivable of $25.6 million and inventory of $40.7 million as of September 30, 2025 [17] Q&A Session Summary Question: Plans for investment in the commercial organization - Management indicated plans to increase the number of sales representatives from four to eight by the end of the year, with expectations to add four more in 2026, focusing on strategic areas [19][21] Question: Growth expectations for the orthobiologics business in 2026 - Management expects low double-digit growth for the orthobiologics business in 2026, while hardware growth remains uncertain [22] Question: Insights on new product launches at NAS - Management highlighted three key products: a new growth factor product, an advanced DBM called Trivium, and the recently launched CollagenX, all of which are expected to enhance the product portfolio [25][26] Question: Year-over-year growth in orthobiologics - The orthobiologics business experienced a 4% growth, driven by the stem cell and amnio product lines, while older demineralized bone products faced declines [30][33] Question: Impact of amnio product pricing changes - The company is well-positioned to benefit from the new pricing structure for amnio products, leveraging strong hospital contracts [38] Question: Plans for distributing CollagenX - Management sees significant potential for CollagenX in various markets, leveraging the existing platform technology acquired through previous acquisitions [40][41]